Published in Clin Cancer Res on August 01, 2007
The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors. Semin Oncol (2012) 1.44
Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. J Transl Med (2009) 1.03
Viral vector-based therapeutic cancer vaccines. Cancer J (2011) 1.00
Development of modified vaccinia Ankara-5T4 as specific immunotherapy for advanced human cancer. Expert Opin Biol Ther (2008) 0.86
Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer. Cancer Immunol Immunother (2008) 0.84
A selectable and excisable marker system for the rapid creation of recombinant poxviruses. PLoS One (2011) 0.82
Immunological off-target effects of standard treatments in gastrointestinal cancers. Ann Oncol (2013) 0.81
Histological evaluation of intratumoral myxoma virus treatment in an immunocompetent mouse model of melanoma. Oncolytic Virother (2013) 0.80
An update on TroVax for the treatment of progressive castration-resistant prostate cancer. Onco Targets Ther (2011) 0.78
Recombinant modified vaccinia virus ankara (MVA) expressing wild-type human p53 induces specific antitumor CTL expansion. Cancer Invest (2011) 0.78
Immunological characterization of a modified vaccinia virus Ankara vector expressing the human papillomavirus 16 E1 protein. Clin Vaccine Immunol (2013) 0.78
Identification of Pre- and Post-Treatment Markers, Clinical, and Laboratory Parameters Associated with Outcome in Renal Cancer Patients Treated with MVA-5T4. Front Oncol (2013) 0.78
TroVax in colorectal cancer. Hum Vaccin Immunother (2014) 0.77
CD8+ T-cell clones specific for the 5T4 antigen target renal cell carcinoma tumor-initiating cells in a murine xenograft model. J Immunother (2012) 0.76
Cancer vaccines: identification of biomarkers predictive of clinical efficacy. Hum Vaccin Immunother (2013) 0.75
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med (2010) 15.71
Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. Nat Med (2011) 3.60
Preoperative portal vein embolization for major liver resection: a meta-analysis. Ann Surg (2008) 3.33
VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature (2004) 3.08
Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med (2005) 2.80
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol (2014) 2.64
A simple method to cure established tumors by inflammatory killing of normal cells. Nat Biotechnol (2004) 2.39
How we do a bloodless partial splenectomy. Am J Surg (2003) 2.26
A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res (2008) 2.18
Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin Cancer Res (2008) 1.91
Endoscopically applied radiofrequency ablation appears to be safe in the treatment of malignant biliary obstruction. Gastrointest Endosc (2011) 1.88
A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J Gen Virol (2004) 1.80
Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy. Nat Med (2007) 1.74
Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy. J Clin Invest (2004) 1.73
Cell carriers for oncolytic viruses: Fed Ex for cancer therapy. Mol Ther (2009) 1.72
Reovirus activates human dendritic cells to promote innate antitumor immunity. J Immunol (2008) 1.70
Impact of margin status on survival following pancreatoduodenectomy for cancer: the Leeds Pathology Protocol (LEEPP). HPB (Oxford) (2009) 1.67
Ultrasound-guided radiofrequency-assisted segmental liver resection: a new technique. Ann Surg (2009) 1.60
A multicenter Phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene. Clin Cancer Res (2004) 1.54
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. J Natl Cancer Inst (2013) 1.54
REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res (2010) 1.53
Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma. Nat Biotechnol (2012) 1.52
Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma. Clin Cancer Res (2009) 1.50
Portal hypertension secondary to 90Yttrium microspheres: an unknown complication. J Clin Oncol (2005) 1.47
Assessment of response to treatment of unresectable liver tumours with 90Y microspheres: value of FDG PET versus computed tomography. Nucl Med Commun (2007) 1.46
Potential uses of microRNA in lung cancer diagnosis, prognosis, and therapy. Curr Cancer Drug Targets (2009) 1.46
Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion. Cancer Res (2002) 1.42
Induction of hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancer. Cancer Res (2007) 1.37
Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA) of the Pancreas in a Porcine Model. Gastroenterol Res Pract (2012) 1.36
Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo. Cancer Res (2005) 1.35
Retinoic acid receptor beta2 promotes functional regeneration of sensory axons in the spinal cord. Nat Neurosci (2005) 1.31
Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res (2010) 1.30
Cloning, expression, and characterization of fimbrial operon F9 from enterohemorrhagic Escherichia coli O157:H7. Infect Immun (2006) 1.30
Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer. Cancer Res (2010) 1.27
Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia. Sci Transl Med (2009) 1.25
The biology of the sodium iodide symporter and its potential for targeted gene delivery. Curr Cancer Drug Targets (2010) 1.25
Short-course radiotherapy, with elective delay prior to surgery, in patients with unresectable rectal cancer who have poor performance status or significant co-morbidity. Radiother Oncol (2009) 1.25
Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin Cancer Res (2006) 1.24
Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice. J Clin Invest (2010) 1.22
Lentivirus-mediated gene transfer to the central nervous system: therapeutic and research applications. Hum Gene Ther (2006) 1.21
Killing of normal melanocytes, combined with heat shock protein 70 and CD40L expression, cures large established melanomas. J Immunol (2006) 1.20
Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study. Clin Cancer Res (2008) 1.20
Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. BMC Cancer (2011) 1.17
Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2. Clin Cancer Res (2009) 1.17
Expression of the CUB domain containing protein 1 (CDCP1) gene in colorectal tumour cells. FEBS Lett (2007) 1.16
Functional cloning of recurrence-specific antigens identifies molecular targets to treat tumor relapse. Mol Ther (2013) 1.16
Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus. Hum Gene Ther (2011) 1.16
Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer. Mol Ther (2008) 1.16
VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling. Mol Ther (2010) 1.15
Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus. Hum Gene Ther (2010) 1.15
Pathogenic potential of emergent sorbitol-fermenting Escherichia coli O157:NM. Infect Immun (2008) 1.14
The integration profile of EIAV-based vectors. Mol Ther (2006) 1.14
Endothelin-2 is a hypoxia-induced autocrine survival factor for breast tumor cells. Mol Cancer Ther (2002) 1.11
Transduction patterns of pseudotyped lentiviral vectors in the nervous system. Mol Ther (2004) 1.11
Retinoic acid receptor beta2 and neurite outgrowth in the adult mouse spinal cord in vitro. J Cell Sci (2002) 1.10
Antitumor immunity can be uncoupled from autoimmunity following heat shock protein 70-mediated inflammatory killing of normal pancreas. Cancer Res (2009) 1.09
Immune suppression uncovers endogenous cytopathic effects of the hepatitis B virus. J Virol (2006) 1.05
MMP-10 is overexpressed, proteolytically active, and a potential target for therapeutic intervention in human lung carcinomas. Neoplasia (2005) 1.05
Evaluation of effects of a novel endoscopically applied radiofrequency ablation biliary catheter using an ex-vivo pig liver. J Hepatobiliary Pancreat Sci (2012) 1.04
Design, production, safety, evaluation, and clinical applications of nonprimate lentiviral vectors. Methods Enzymol (2002) 1.04
Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune priming. Mol Cancer (2011) 1.04
Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples. Mod Pathol (2012) 1.03
Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. J Transl Med (2009) 1.03
Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Cancer Immunol Immunother (2008) 1.03
Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial. J Immunother (2008) 1.03
Management and prevention of adverse effects related to treatment of liver tumours with 90Y microspheres. Nucl Med Commun (2007) 1.03
Elucidating variations in the nucleotide sequence of Ebola virus associated with increasing pathogenicity. Genome Biol (2014) 1.01
Identification and functional validation of MHC class I epitopes in the tumor-associated antigen 5T4. Int Immunol (2008) 1.01
Percutaneous intraductal radiofrequency ablation is a safe treatment for malignant biliary obstruction: feasibility and early results. Cardiovasc Intervent Radiol (2012) 1.00
Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus. Mol Ther (2008) 1.00
Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated. Cancer Immunol Immunother (2005) 0.99
Recombinant viral vectors: cancer vaccines. Adv Drug Deliv Rev (2006) 0.99
Exploiting synergies between radiation and oncolytic viruses. Curr Opin Mol Ther (2008) 0.99
Experimental and clinical radiofrequency ablation: proposal for standardized description of coagulation size and geometry. Ann Surg Oncol (2007) 0.98
Crystal structure of the essential transcription antiterminator M2-1 protein of human respiratory syncytial virus and implications of its phosphorylation. Proc Natl Acad Sci U S A (2014) 0.96
Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial. J Immunother (2009) 0.95
Transduction of photoreceptors with equine infectious anemia virus lentiviral vectors: safety and biodistribution of StarGen for Stargardt disease. Invest Ophthalmol Vis Sci (2013) 0.95
A quantitative proteomic analysis of lung epithelial (A549) cells infected with 2009 pandemic influenza A virus using stable isotope labelling with amino acids in cell culture. Proteomics (2012) 0.95
Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide. Mol Ther (2010) 0.95
Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma. Cancer Gene Ther (2002) 0.94
Protein crystals in Adenovirus type 5-infected cells: requirements for intranuclear crystallogenesis, structural and functional analysis. PLoS One (2008) 0.93